| Literature DB >> 35838886 |
Sahabjada Siddiqui1, Shivbrat Upadhyay2, Rumana Ahmad3, Md Abul Barkat4, Azfar Jamal5,6, Abdulaziz S Alothaim6, Mohd Zaheen Hassan7, Mohammad Akhlaquer Rahman8, Md Arshad9, Tanveer Ahamad2, Mohammad Faheem Khan2, Hari Shankar10, M Ali11, Sarjeel Kaleem12, Jalal Ahmad13.
Abstract
Novel SARS-CoV-2 claimed a large number of human lives. The main proteins for viral entry into host cells are SARS-CoV-2 spike glycoprotein (PDB ID: 6VYB) and spike receptor-binding domain bound with ACE2 (spike RBD-ACE2; PDB ID: 6M0J). Currently, specific therapies are lacking globally. This study was designed to investigate the bioactive components from Moringa oleifera leaf (MOL) extract by gas chromatography-mass spectroscopy (GC-MS) and their binding interactions with spike glycoprotein and spike RBD-ACE2 protein through computational analysis. GC-MS-based analysis unveiled the presence of thirty-seven bioactive components in MOL extract, viz. polyphenols, fatty acids, terpenes/triterpenes, phytosterols/steroids, and aliphatic hydrocarbons. These bioactive phytoconstituents showed potential binding with SARS-CoV-2 spike glycoprotein and spike RBD-ACE2 protein through the AutoDock 4.2 tool. Further by using AutoDock 4.2 and AutoDock Vina, the top sixteen hits (binding energy ≥ - 6.0 kcal/mol) were selected, and these might be considered as active biomolecules. Moreover, molecular dynamics simulation was determined by the Desmond module. Interestingly two biomolecules, namely β-tocopherol with spike glycoprotein and β-sitosterol with spike RBD-ACE2, displayed the best interacting complexes and low deviations during 100-ns simulation, implying their strong stability and compactness. Remarkably, both β-tocopherol and β-sitosterol also showed the drug- likeness with no predicted toxicity. In conclusion, these findings suggested that both compounds β-tocopherol and β-sitosterol may be developed as anti-SARS-CoV-2 drugs. The current findings of in silico approach need to be optimized using in vitro and clinical studies to prove the effectiveness of phytomolecules against SARS-CoV-2.Entities:
Keywords: GC–MS analysis; Molecular docking; Moringa oleifera leaf; Phytoconstituents; SARS-CoV-2
Year: 2022 PMID: 35838886 PMCID: PMC9283843 DOI: 10.1007/s12010-022-04040-1
Source DB: PubMed Journal: Appl Biochem Biotechnol ISSN: 0273-2289 Impact factor: 3.094
Fig. 1GC–MS total ion chromatogram (TIC) of the 95% ethanolic extract of Moringa oleifera leaf. Total ion current is represented by Y-axis and retention time by X-axis
Identification of phytoconstituents from 95% ethanolic Moringa oleifera leaf extract by GC–MS analysis
Docking effects of identified MOL phytoconstituents with spike glycoprotein (PDB ID: 6VYB) of SARS-CoV-2 through AutoDock 4.2 and AutoDockVina. AccelrysBiovia Discovery Studio version 2017 R2 was used to visualize interacting amino acid residues. In AutoDock 4.2, the ligand–protein interaction is represented by Ball and Stick model, while in AutoDockVina, it is represented by a 2-D line model. Dark green-dotted line represents the H-bond, and the alkyl and pi-alkyl bond interactions are represented by magenta broken lines
Docking interactions of identified MOL phytoconstituents with SARS-CoV-2 spike receptor-binding domain bound with ACE2 (spike RBD-ACE2; PDB ID: 6M0J) using AutoDock 4.2 and AutoDockVina. AccelrysBiovia Discovery Studio version 2017 R2 was used to visualize interacting amino acid residues. In AutoDock 4.2, the ligand–protein interaction is represented by Ball and Stick model, while in AutoDockVina, it is represented by a 2-D line model. Dark green-dotted line represents the H-bond, whereas the alkyl and pi-alkyl bond interactions are represented by magenta broken lines
Fig. 2Molecular dynamics simulation of ligands in complex with proteins of SARS-CoV-2 during 100-ns time scale. A and D RMSD value of β-tocopherol in complex with spike glycoprotein (PDB ID: 6VYB) and β-sitosterol in complex with spike receptor-binding domain bound with ACE2 (spike RBD-ACE2; PDB ID: 6M0J), respectively, which was obtained from three independent 100-ns runs. B and E RMSF value of β-tocopherol in complex with spike glycoprotein (PDB ID: 6VYB) and β-sitosterol in complex with spike receptor-binding domain bound with ACE2 (spike RBD-ACE2; PDB ID: 6M0J), respectively, at 100-ns simulation run from three independent runs. The curve in light blue curves shows protein residue fluctuations, and green-colored vertical bars display the protein residues interacting with ligand. The α-helical and β-strand regions are highlighted in red and blue backgrounds, respectively. C and F Showing characterizing changes in the ligand atom positions of β-tocopherol and β-sitosterol RMSF, respectively
Fig. 3Interaction diagram of ligands with SARS-CoV-2 protein during 100-ns simulation. A and D A schematic of detailed β-tocopherol atom interactions with spike glycoprotein (PDB ID: 6VYB) amino acid residues and β-sitosterol with spike receptor-binding domain bound with ACE2 (spike RBD-ACE2; PDB ID: 6M0J) amino acid residues, respectively. The selected trajectory displays interactions that take up more than 30% of the simulation run time. B and E The interaction fraction of β-tocopherol with spike glycoprotein and β-sitosterol with spike RBD-ACE2 was determined during 100-ns simulation. As seen in the plot above, these interactions can be classified depending upon interaction type. Hydrophobic, hydrogen bond, ionic, and water bridges are the four forms of protein–ligand interactions (or “contacts”). C and F A timeline illustrations of the interactions and contacts of β-tocopherol with spike glycoprotein and β-sitosterol with spike RBD-ACE2, respectively. The total number of specific contacts the protein makes with the ligand during the course of the trajectory is shown in the top panel. In each trajectory frame, the bottom panel displays the residues interacting with the ligand. As per the scale to the right of the plot, the residues making many contact are displayed by a darker shade of orange
A detailed interaction of amino acid residues of spike glycoprotein- β-tocopherol complex and spike-RBD-ACE2 protein- β sitosterol in protein–ligand contact analysis
| Protein–ligand contact analysis | |||
|---|---|---|---|
| S. no | Interaction | Spike glycoprotein- β-tocopherol complex | Spike-RBD-ACE2 protein- β sitosterol |
| 1 | H-bonds | A: Gln 1002, Gln 1005, Thr1006 B: Gln 1005 C: Thr1009 | Ser 43, Ser44, Ser 47, Met62, Asn63, Asp 67, Lys74, Ser106, Asn121, Ala348, Glu375, His378, His505, Asn508 |
| 2 | Hydrophobic | C: Phe 759, Leu763, Ala766, Gln1005, Val1008, Leu1012 | Phe 32, Phe40, Met62, Trp69, Leu73, Ala99, Leu100, Ala348, Tyr385, Phe390, Leu391, Tyr510 |
| 3 | Ionic | ||
| 4 | Water bridges | B: Gln 1005 | Ser43, Ser47, Asn 51,Met62, Asn63, Asp 67, Ser70, Lys 74, Ser105, Ser106, Lys114, Asn117, Leu120, Asn121, Ser124, His345, Pro346, Thr347, Ala348, His374, Glu375, His378, Glu402, Glu406, His505, Asn508, Tyr510, Ser511, Tyr515 |
PASS analysis of identified bioactive chemicals from MOL extract
| S. no | Phytoconstituents | % Absorptiona (> 50%) | Topological polar surface area (TPSA) (Å)2, b | MW (≤ 500) | c logPc (≤ 5) | Heavy atom count (n atoms) | Hydrogen bond donors (nOHNH) (≤ 5) | Hydrogen bond acceptors (nON) (≤ 10) | Number of rotatable bonds (≤ 10) | Lipinski’s violation |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | N-(3-Aminopropyl)morpholine | 95.72 | 38.49 | 144.2 | − 0.75 | 10 | 2 | 3 | 3 | 0 |
| 2 | 2-Benzylpiperidine | 104.84 | 12.03 | 175.28 | 2.80 | 13 | 1 | 1 | 2 | 0 |
| 3 | Guanosine | 53.96 | 159.52 | 283.24 | 2.02 | 20 | 6 | 10 | 2 | 1 |
| 4 | Hexatriacontane | 0.0 | 0.0 | 506.99 | 10.47 | 36 | 0 | 0 | 33 | 2 |
| 5 | 2,8-dimethyl-2-(4,8,12-trimethyltridecyl)-6-chromanol | 79.00 | 86.95 | 322.41 | − 0.74 | 23 | 2 | 7 | 3 | 0 |
| 6 | beta.-Tocopherol | 98.83 | 29.46 | 416.69 | 8.98 | 30 | 1 | 2 | 12 | 1 |
| 7 | gamma.-Tocopherol | 98.83 | 29.46 | 416.69 | 8.98 | 30 | 1 | 2 | 12 | 1 |
| 8 | Campesterol | 102.02 | 20.23 | 400.69 | 8.30 | 29 | 1 | 1 | 5 | 1 |
| 9 | dl-.alpha.-Tocopherol | 98.83 | 29.46 | 430.72 | 9.04 | 31 | 1 | 2 | 12 | 1 |
| 10 | Stigmasta-5,22-dien-3-ol, (3.beta.,22e)- | 102.02 | 20.23 | 412.70 | 7.87 | 30 | 1 | 1 | 5 | 1 |
| 11 | BetaSitosterol | 102.02 | 20.23 | 414.72 | 8.62 | 30 | 1 | 1 | 6 | 1 |
| 12 | Fucosterol | 102.02 | 20.23 | 412.70 | 7.69 | 30 | 1 | 1 | 5 | 1 |
| 13 | Lupeol | 102.02 | 20.23 | 426.73 | 8.29 | 31 | 1 | 1 | 1 | 0 |
| 14 | Hexacosane | 0.0 | 0.00 | 366.72 | 9.91 | 26 | 0 | 0 | 23 | 1 |
| 15 | Squalene | 0.0 | 0.00 | 410.73 | 9.62 | 30 | 0 | 0 | 15 | 1 |
| 16 | E,E,Z-1,3,12-Nonadecatriene-5,14-diol | 95.04 | 40.46 | 294.48 | 5.95 | 21 | 2 | 2 | 14 | 1 |
RULE:
aPercentage absorption was calculated as: % Absorption = 109- [0.345 × TPSA]
bTopological polar surface area (defined as a sum of surfaces of polar atoms in a molecule)
cLogarithm of compound partition coefficient between n-octanol and water
Drug likeness and toxicity calculation of MOL phytoconstituents
| S. no | Compound name | Drug- likeness | Mutant | Tumurogenic | Reproductive effective | Irritant |
|---|---|---|---|---|---|---|
| 1 | N-(3-Aminopropyl)morpholine | 0.075381 | N | N | N | N |
| 2 | 2-Benzylpiperidine | − 0.7075 | N | N | N | N |
| 3 | Guanosine | − 1.348 | N | N | N | N |
| 4 | Hexatriacontane | − 20.398 | N | N | N | N |
| 5 | 2,8-dimethyl-2-(4,8,12-trimethyltridecyl)-6-chromanol | 9.3678 | N | N | L | N |
| 6 | Beta-Tocopherol | − 3.2757 | N | N | N | N |
| 7 | Gamma-Tocopherol | − 3.2757 | N | N | N | N |
| 8 | Campesterol | − 8.1908 | N | N | N | N |
| 9 | dl-alpha-Tocopherol | − 3.2757 | N | N | N | N |
| 10 | Stigmasta-5,22-dien-3-ol, (3.beta.,22e)- | 1.2217 | N | N | N | N |
| 11 | Beta-Sitosterol | − 4.475 | N | N | N | N |
| 12 | Fucosterol | − 6.2842 | N | N | N | H |
| 13 | Lupeol | − 22.172 | N | N | N | N |
| 14 | Hexacosane | − 20.398 | N | N | N | N |
| 15 | Squalene | − 3.5218 | N | N | N | N |
| 16 | E,E,Z-1,3,12-Nonadecatriene-5,14-diol | − 20.672 | N | N | N | H |
N no toxicity
L low toxicity
H high toxicity
Calculation of ADMET properties of MOL phytocomponents using online SwissADME software
| S. no | Phytocomponents | Lipophilicity (consensus Log Po/w) | BBB permeant | P-gp substrate | CYP1A2 inhibitor | CYP2C19 inhibitor | CYP2C9 inhibitor | CYP2D6 inhibitor | CYP3A4 inhibitor | Log Kp (skin permeation) | GI absorption |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | N-(3-Aminopropyl)morpholine | 0.15 | No | No | No | No | No | No | No | − 7.67 | High |
| 2 | 2-Benzylpiperidine | 2.60 | Yes | No | No | No | No | Yes | No | − 5.48 | High |
| 3 | Guanosine | − 2.02 | No | No | No | No | No | No | No | − 9.37 | Low |
| 4 | Hexatriacontane | 13.67 | No | Yes | No | No | No | No | No | 4.18 | Low |
| 5 | 2,8-dimethyl-2-(4,8,12-trimethyltridecyl)-6-chromanol | 7.58 | No | Yes | No | No | No | No | No | − 1.68 | Low |
| 6 | Beta-Tocopherol | 7.79 | No | Yes | No | No | No | No | No | − 1.51 | Low |
| 7 | Gamma-Tocopherol | 7.95 | No | Yes | No | No | No | No | No | − 1.51 | Low |
| 8 | Campesterol | 6.90 | No | No | No | No | No | No | No | − 2.50 | Low |
| 9 | dl-alpha-Tocopherol | 8.27 | No | Yes | No | No | No | No | No | − 1.33 | Low |
| 10 | Stigmasta-5,22-dien-3-ol, (3.beta.,22e)- | 6.97 | No | Yes | No | No | Yes | No | No | − 2.74 | Low |
| 11 | Beta-Sitosterol | 7.19 | No | No | No | No | No | No | No | − 2.20 | Low |
| 12 | Fucosterol | 7.07 | No | No | No | No | No | No | No | − 2.53 | Low |
| 13 | Lupeol | 7.26 | No | No | No | No | No | No | No | − 1.90 | Low |
| 14 | Hexacosane | 10.09 | No | Yes | No | No | No | No | No | 1.19 | Low |
| 15 | Squalene | 9.38 | No | No | No | No | No | No | No | − 0.58 | Low |
| 16 | E,E,Z-1,3,12-Nonadecatriene-5,14-diol | 4.94 | Yes | Yes | Yes | No | Yes | Yes | Yes | − 4.08 | High |
Fig. 4Pictorial representation of the phytochemical analysis and in silico antiviral drug development evaluation of Moringa oleifera phytoconstituents